Amsterdam, 07 June 2007 -- Elsevier, a world-leading healthcare and scientific publisher, announced today, that it has renewed its agreement with AdvantTechnologies (aTi) paving the way for the launch of the Inteleos Universal IntegratorTM (UI) a revolutionary tool to integrate information on drug pipeline research from multiple sources.
With the Inteleos UI, pharmaceutical and biotech professionals will be able to compare and contrast information from multiple data sources – both internal and external to their organization – streamlining the data collection, analysis and decision making process. The single, intuitive interface presents information from disparate sources in a comprehensive, integrated format that is quick and easy to use.
The Inteleos UI is the first product to offer the ability to conduct single searches across multiple databases. An expanded ontology of scientific terms gives users the ability to conduct an exhaustive search. Advanced functionality includes the ability to “drill down” to the desired level of detail and automatic alerts when there are changes in the data sources.
“It is our quest to develop products that enhance the workflow of researchers,” explains CEO of Elsevier Health Sciences, Brian Nairn. “The agreement with aTi is testament to our commitment to coupling quality content with technology to enhance the research process for business and market intelligence professionals.”
Updated daily, using only primary sources, Inteleos content is structured for maximum user-friendliness and indexed and searchable to meet today’s scientific challenges, including biologics and comprehensive coverage of FDA regulatory filings. Inteleos is the most intuitive, flexible tool for drug pipeline research, tracking and analysis.
For more information on Inteleos please visit www.inteleos.com.
About AdvanTechnologies Inc.
Founded by world-renowned IT researchers, AdvanTechnologies (aTi) (http://www.advantechnologies.com) provides state-of-the-art Knowledge Management Enabling software products and associated decision support tools targeted to the pharmaceutical, biomedical and healthcare industries.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).